Feb 03, 2022
- Corporate
Notice of Changes in Representative Directors and Directors
| Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
| Code number: | 4519 (1st Section of Tokyo Stock Exchange) |
| Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
| President & CEO: | Osamu Okuda |
| Inquiries to: | Toshiya Sasai |
| Head of Corporate Communications Dept. | |
| Tel:+81-(0)3-3273-0554 |
Chugai Pharmaceutical Co., Ltd. (the “Company”) announces changes in Representative Directors and Directors with the resolution of the Board of Directors Meeting held on February 3, 2022, as described below. The changes will be formalized after the Annual General Meeting of Shareholders and the Board of Directors Meeting scheduled on March 29, 2022.
1. Change in Representative Directors
(1) Reason for Change
Since the conclusion of the strategic alliance agreement with Roche in 2001, the Company has been working diligently to establish a unique business model. In order to achieve sustainable growth and development of the Chugai group and further enhance the corporate value through promoting our growth strategy “TOP I 2030” under a new management structure in 2022, Tatsuro Kosaka, Representative Director and Chairman, and Motoo Ueno, Representative Director and Deputy Chairman will retire, and Executive Vice Presidents, Hisafumi Yamada and Toshiaki Itagaki will be appointed as Directors.
(2) Retiring Representative Directors
| Name | Current Title |
| Tatsuro Kosaka | Representative Director, Chairman |
| Motoo Ueno | Representative Director, Deputy Chairman |
*Tatsuro Kosaka and Motoo Ueno are expected to be appointed as Senior Advisors.
**Osamu Okuda is expected to be appointed as Chairman of the Board of Directors.
(3) Effective Date
March 29, 2022
2. Change in Directors
(1) Newly Appointed Directors
| Name | New Title | Current Title |
| Hisafumi Yamada | Director, Executive Vice President Supervisory responsibility for Project & Lifecycle Management (R&D), Research, Translational Research, Clinical Development, and Pharmaceutical Technology |
Executive Vice President Supervisory responsibility for Project & Lifecycle Management (R&D), Research, and Translational Research |
| Toshiaki Itagaki | Director, Executive Vice President Chief Financial Officer (CFO) Supervisory responsibility for Finance & Accounting, Corporate Communication, and Purchasing Head of Finance Supervisory Div. |
Executive Vice President Chief Financial Officer (CFO) Supervisory responsibility for Finance & Accounting, Corporate Communication, Purchasing, and Digital Transformation Head of Finance Supervisory Div. |
(2) Effective Date
March 29, 2022
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
